View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

International Flavors & Fragrances Inc: 1 director

A director at International Flavors & Fragrances Inc bought 25,000 shares at 73.970USD and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

 PRESS RELEASE

Fluent, Inc. and Rebuy Partner to Unlock Post-Purchase Advertising for...

Fluent, Inc. and Rebuy Partner to Unlock Post-Purchase Advertising for Shopify Merchants NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a leading provider of commerce media solutions, and Rebuy Engine, a leading ecommerce personalization platform for Shopify brands, have announced a strategic partnership to launch Rebuy Ads powered by Fluent, a new product offering designed to help merchants further engage their customers while unlocking additional revenue at no cost. Unparalleled Scale and Insights Rebuy Engine is uniquely positioned to drive impact at scale, g...

 PRESS RELEASE

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright B...

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexico...

 PRESS RELEASE

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results...

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at ...

 PRESS RELEASE

OPKO Health Reports First Quarter 2025 Business Highlights and Financi...

OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference’s laboratory te...

 PRESS RELEASE

OPKO Health to Report First Quarter 2025 Financial Results on April 30...

OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to p...

 PRESS RELEASE

Fluent, Inc. Unveils Enhanced Identity Graph to Power Smarter Personal...

Fluent, Inc. Unveils Enhanced Identity Graph to Power Smarter Personalization and Campaign Performance Strategic partnership with Experian drives sharper audience targeting and greater revenue impact across commerce media solutions NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a leading commerce media solutions company, today announced the release of its enhanced Fluent Identity Graph, designed to scale personalization and optimize results for advertisers, partners, and consumers across its suite of commerce media solutions. Fluent’s identity graph is a key ...

 PRESS RELEASE

OPKO Health Announces $100 Million Increase to its Existing Share Repu...

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO’s common stock has been repurchased under the existing program since its authorization in July 2024. “We believe OPKO’s shares continue to be significantly undervalued and offer an attractive...

 PRESS RELEASE

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual ...

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medici...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of International Flavors & Fragrances, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 March 2025 in which we reassessed the appropriateness of the ra...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: April 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: March 28, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Nov...

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the...

 PRESS RELEASE

Fluent, Inc. Announces $5.0 Million Private Offering

Fluent, Inc. Announces $5.0 Million Private Offering NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Fluent, Inc. (NASDAQ: FLNT), a commerce media solutions company, today announced that it will issue unregistered pre-funded warrants to purchase up to 2,332,104 shares of its common stock at a purchase price of $2.174 in a private offering. The exercisability of the pre-funded warrants will be subject to stockholder approval, which the Company shall seek at its next annual meeting of stockholders. If such stockholder approval is obtained, the pre-funded warrants may be exercised at any time a...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch